Literature DB >> 6347236

Immunofluorescence identification of eosinophil granule major basic protein in the flame figures of Wells' syndrome.

M S Peters, A L Schroeter, G J Gleich.   

Abstract

An indirect immunofluorescence assay using formalin-fixed paraffin-embedded skin was performed on six biopsies from four patients with eosinophilic cellulitis (Wells' syndrome) to determine the extracellular localization of eosinophil granule major basic protein (MBP). Serial sections from each biopsy were treated with either affinity chromatography-purified antihuman-MBP or staphylococcal protein A purified rabbit IgG (control material). There was striking extracellular fluorescence localized to flame figures, and intracellular staining of eosinophils in all sections treated with anti-MBP as compared with controls. The pattern of MBP extracellular staining corresponded to the configuration of each flame figure (as verified by counterstain of the same section with haematoxylin and eosin). These findings show that MBP can be used as a marker for determining eosinophil degranulation and, because MBP is localized to flame figures, they suggest that MBP may play a pathogenic role in Wells' syndrome.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6347236     DOI: 10.1111/j.1365-2133.1983.tb07074.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  11 in total

1.  Toxicity of eosinophil MBP is repressed by intracellular crystallization and promoted by extracellular aggregation.

Authors:  Alice Soragni; Shida Yousefi; Christina Stoeckle; Angela B Soriaga; Michael R Sawaya; Evelyne Kozlowski; Inès Schmid; Susanne Radonjic-Hoesli; Sebastien Boutet; Garth J Williams; Marc Messerschmidt; M Marvin Seibert; Duilio Cascio; Nadia A Zatsepin; Manfred Burghammer; Christian Riekel; Jacques-Philippe Colletier; Roland Riek; David S Eisenberg; Hans-Uwe Simon
Journal:  Mol Cell       Date:  2015-02-26       Impact factor: 17.970

2.  [Leucocytoclastic eosinophilic vasculitis with Löffler syndrome].

Authors:  P-G Sator; R Feldmann; T Wanke; F Gschnait; F Breier
Journal:  Hautarzt       Date:  2007-05       Impact factor: 0.751

3.  CCR3 is essential for skin eosinophilia and airway hyperresponsiveness in a murine model of allergic skin inflammation.

Authors:  Weilie Ma; Paul J Bryce; Alison A Humbles; Dhafer Laouini; Ali Yalcindag; Harri Alenius; Daniel S Friend; Hans C Oettgen; Craig Gerard; Raif S Geha
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

Review 4.  Clinical overview of cutaneous features in hypereosinophilic syndrome.

Authors:  Sabine Gisela Plötz; Bettina Hüttig; Birgit Aigner; Christian Merkel; Knut Brockow; Cezmi Akdis; Ulf Darsow; Johannes Ring
Journal:  Curr Allergy Asthma Rep       Date:  2012-04       Impact factor: 4.806

5.  Deposition of eosinophil cationic protein in granulomas in allergic granulomatosis and vasculitis: the Churg-Strauss syndrome.

Authors:  P C Tai; M E Holt; P Denny; A R Gibbs; B D Williams; C J Spry
Journal:  Br Med J (Clin Res Ed)       Date:  1984-08-18

6.  Wells syndrome (eosinophilic cellulitis): Proposed diagnostic criteria and a literature review of the drug-induced variant.

Authors:  Kara Heelan; John F Ryan; Neil H Shear; Conleth A Egan
Journal:  J Dermatol Case Rep       Date:  2013-12-30

7.  An immunofluorescent method for a specific demonstration of granulocytes and some of their proteins (ECP and CCP).

Authors:  K Fredens; R Dahl; P Venge
Journal:  Histochemistry       Date:  1986

Review 8.  [Eosinophilic dermatoses].

Authors:  G Wozel
Journal:  Hautarzt       Date:  2007-04       Impact factor: 0.751

9.  IL-10 is critical for Th2 responses in a murine model of allergic dermatitis.

Authors:  Dhafer Laouini; Harri Alenius; Paul Bryce; Hans Oettgen; Erdyni Tsitsikov; Raif S Geha
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

Review 10.  Eosinophils in skin diseases.

Authors:  Susanne Radonjic-Hoesli; Marie-Charlotte Brüggen; Laurence Feldmeyer; Hans-Uwe Simon; Dagmar Simon
Journal:  Semin Immunopathol       Date:  2021-06-07       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.